R K Marwaha1, K P Kulkarni, D Bansal, A Trehan. 1. Division of Pediatric Hematology-Oncology, Advanced Pediatric Center, PGIMER, Chandigarh, India. rammarwaha1@rediffmail.com
Abstract
OBJECTIVE: To analyze the prognostic impact of overt testicular disease (OTD) at diagnosis and role of testicular irradiation in the same. METHODS: Data of 579 boys treated at our center over 16 years was reviewed. RESULTS: Fourteen (2.4%) males had OTD. 10 (71.4%) of these had high-risk disease. Patients with OTD, had a significantly higher incidence of mediastinal-adenopathy (p=0.001), hyperleucocytosis (p=0.004) and CNS disease at presentation (p<0.0001) compared to patients in continuous complete remission (CCR). 4 of the 11 patients with OTD, who opted for therapy, had relapse; 2 are in CCR. Although, survival in patients with OTD was inferior (p=0.183) compared to patients without OTD, it was not an independent prognostic factor (p=0.47). In the entire study cohort, symptom-diagnosis interval (p=0.006), white cell (p=0.001) and platelet count (p=0.001) at presentation were significantly associated with survival (Cox multivariate regression analysis). CONCLUSIONS: OTD was not an independent prognostic factor, despite association with high-risk features. Survival outcome was inferior. The observations indicate the need of revaluation of the present protocol with incorporation of intermediate dose and subsequently high-dose methotrexate (after assessment for toxicity and tolerance), risk-stratified therapy and plausibly omission of testicular irradiation.
OBJECTIVE: To analyze the prognostic impact of overt testicular disease (OTD) at diagnosis and role of testicular irradiation in the same. METHODS: Data of 579 boys treated at our center over 16 years was reviewed. RESULTS: Fourteen (2.4%) males had OTD. 10 (71.4%) of these had high-risk disease. Patients with OTD, had a significantly higher incidence of mediastinal-adenopathy (p=0.001), hyperleucocytosis (p=0.004) and CNS disease at presentation (p<0.0001) compared to patients in continuous complete remission (CCR). 4 of the 11 patients with OTD, who opted for therapy, had relapse; 2 are in CCR. Although, survival in patients with OTD was inferior (p=0.183) compared to patients without OTD, it was not an independent prognostic factor (p=0.47). In the entire study cohort, symptom-diagnosis interval (p=0.006), white cell (p=0.001) and platelet count (p=0.001) at presentation were significantly associated with survival (Cox multivariate regression analysis). CONCLUSIONS: OTD was not an independent prognostic factor, despite association with high-risk features. Survival outcome was inferior. The observations indicate the need of revaluation of the present protocol with incorporation of intermediate dose and subsequently high-dose methotrexate (after assessment for toxicity and tolerance), risk-stratified therapy and plausibly omission of testicular irradiation.
Authors: S J Vaidya; S H Advani; S K Pai; C N Nair; P A Kurkure; T K Saikia; R Gopal; V R Pai; K S Nadkarni; P M Parikh Journal: Leuk Lymphoma Date: 1996-01
Authors: S H Advani; R S Iyer; S K Pai; R Gopal; T K Saikia; C N Nair; P A Kurkure; K S Nadkarni; V R Pai Journal: Am J Hematol Date: 1992-04 Impact factor: 10.047
Authors: N Hijiya; W Liu; J T Sandlund; S Jeha; B I Razzouk; R C Ribeiro; J E Rubnitz; S C Howard; E P Kyzer; D S Redd; C Cheng; G K Rivera; M M Hudson; M V Relling; C-H Pui Journal: Leukemia Date: 2005-08 Impact factor: 11.528
Authors: Nicolas Sirvent; Stefan Suciu; Yves Bertrand; Anne Uyttebroeck; Brigitte Lescoeur; Jacques Otten Journal: Pediatr Blood Cancer Date: 2007-09 Impact factor: 3.167
Authors: A Gajjar; R C Ribeiro; H H Mahmoud; J T Sandlund; Q Liu; W L Furman; V M Santana; W M Crist; G K Rivera; C H Pui Journal: Cancer Date: 1996-12-01 Impact factor: 6.860
Authors: M L Brecher; V Weinberg; J M Boyett; L F Sinks; B Jones; A Glicksman; J F Holland; A I Freeman Journal: Cancer Date: 1986-09-01 Impact factor: 6.860
Authors: C H Pui; H H Mahmoud; G K Rivera; M L Hancock; J T Sandlund; F G Behm; D R Head; M V Relling; R C Ribeiro; J E Rubnitz; L E Kun; W E Evans Journal: Blood Date: 1998-07-15 Impact factor: 22.113